AbbVie Inc.

Equities

ABBV

US00287Y1091

Real-time Estimate Cboe BZX Other stock markets 21:00:06 17/02/2026 GMT			5-day change	1st Jan Change
232.72 ^USD	+0.53%		+4.70%	+1.93%

04:03pm	Mubadala Investment Co PJSC reports share stake in Pfizer, AbbVie, dissolves in Merck, Dell	RE
03:19pm	HSBC Adjusts Price Target on AbbVie to $275 From $265, Maintains Buy Rating	MT

Transcript : AbbVie Inc. Presents at 44th Annual J.P. Morgan Healthcare Conference, Jan-14-2026 08

Published on 01/14/2026 at 05:35 pm GMT - Modified on 01/14/2026 at 10:03 pm GMT

S&P Capital IQ

Presenter Speech
Christopher Schott (Analysts)

Good morning, everybody. I'm Chris Schott at JPMorgan, and it's my pleasure to be hosting this fireside chat today with AbbVie. From the company, we have

This article is reserved for subscribers

Unlock the article : SUBSCRIBE!

Already a customer? Log In

Latest news about AbbVie Inc.

04:03pm	Mubadala Investment Co PJSC reports share stake in Pfizer, AbbVie, dissolves in Merck, Dell	RE
03:19pm	HSBC Adjusts Price Target on AbbVie to $275 From $265, Maintains Buy Rating	MT
02-13	AbbVie Inc. Presents at Piper Sandler Virtual Novel Targets in Immunology Symposium, Feb-13-2026 10:00 AM
02-13	China Medical University Hospital Collaborates with Ever Supreme Bio Technology to Develop Exosome Platform	CI
02-12	AbbVie sues US health agency over Botox price controls	RE
02-12	West Pharma forecasts 2026 profit above estimates on strong demand for drug components	RE
02-12	West Pharma forecasts 2026 profit above estimates on strong demand for drug components	RE
02-12	West Pharma forecasts 2026 profit above estimates on strong demand for drug components	RE
02-12	West Pharmaceutical Services, Inc. Provides Earnings Guidance for the First Quarter and Full Year 2026	CI
02-11	AbbVie sues US Health Department over Botox price controls	RE
02-11	AbbVie sues US health agency over Botox	RE
02-11	AbbVie sues U.S. Department of Health and Human Services over selection of Botox for IRA Medicare drug negotiations	RE
02-09	BNP Paribas Exane Adjusts Price Target on AbbVie to $213 From $203, Maintains Neutral Rating	MT
02-05	CVS Health to drop Amgen and Lilly's bone disease treatments from some drug lists (February 5)	RE
02-05	Evercore ISI Adjusts Price Target on AbbVie to $228 From $232, Maintains Outperform Rating	MT